Undiscovered Gems In India Akums Drugs and Pharmaceuticals And 2 Promising Small Caps

In This Article:

In the last week, the Indian market has been flat; however, it has shown significant growth over the past year with a 40% increase and an annual earnings forecast of 17%. In this dynamic environment, identifying promising small-cap stocks like Akums Drugs and Pharmaceuticals can be key to uncovering potential opportunities in India's burgeoning market.

Top 10 Undiscovered Gems With Strong Fundamentals In India

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Shree Digvijay Cement

0.01%

13.97%

16.37%

★★★★★★

Vidhi Specialty Food Ingredients

7.27%

11.00%

4.02%

★★★★★★

Le Travenues Technology

10.32%

26.39%

67.32%

★★★★★★

ELANTAS Beck India

NA

14.89%

24.83%

★★★★★★

Timex Group India

14.33%

17.75%

59.68%

★★★★★★

Wealth First Portfolio Managers

4.08%

-43.42%

42.63%

★★★★★☆

Network People Services Technologies

0.11%

84.31%

84.48%

★★★★★☆

Insolation Energy

88.64%

163.87%

419.31%

★★★★★☆

Shree Pushkar Chemicals & Fertilisers

22.85%

17.68%

3.50%

★★★★☆☆

Vasa Denticity

0.11%

38.37%

48.77%

★★★★☆☆

Click here to see the full list of 466 stocks from our Indian Undiscovered Gems With Strong Fundamentals screener.

Here's a peek at a few of the choices from the screener.

Akums Drugs and Pharmaceuticals

Simply Wall St Value Rating: ★★★★★☆

Overview: Akums Drugs and Pharmaceuticals Limited is engaged in the manufacturing and sale of pharmaceutical products and active pharmaceutical ingredients both in India and internationally, with a market capitalization of ?143.23 billion.

Operations: Akums generates revenue primarily from its CDMO segment, contributing ?36.32 billion, followed by branded and generic formulations at ?6.76 billion, and APIs at ?3.03 billion.

Akums Drugs and Pharmaceuticals, a promising player in India's pharmaceutical scene, has shown resilience with a net debt to equity ratio of 40%, indicating satisfactory leverage. Its interest payments are well covered by EBIT at 9.7x, showcasing strong financial health. Recent developments include an exclusive agreement with Triple Hair Inc., enhancing its market reach in India. The company reported a net income of ?601.71 million for Q1 2024, reversing from a loss the previous year. With high-quality earnings and strategic partnerships, Akums is poised for impactful growth in the Indian pharmaceutical market.

NSEI:AKUMS Debt to Equity as at Oct 2024
NSEI:AKUMS Debt to Equity as at Oct 2024

IFB Industries

Simply Wall St Value Rating: ★★★★★☆

Overview: IFB Industries Limited, with a market cap of ?92.00 billion, operates in the manufacturing and trading of home appliances both in India and internationally.